Kidiamix G Start (Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine)

The formulation delivers a balanced set of essential amino acids directly into the bloodstream. These amino acids become substrates for protein synthesis, support nitrogen balance, and participate in metabolic pathways like gluconeogenesis, helping maintain tissue integrity when oral intake is not possible.

The dose of Kidiamix G Start is individualized. A qualified prescriber determines the amount based on the patient’s weight, clinical condition, and nutritional requirements, following established parenteral nutrition protocols.

Safety data for Kidiamix G Start in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Kidiamix G Start offers a comprehensive profile of essential amino acids in a single formulation, matching or exceeding the amino acid composition of many standard parenteral mixes. Its EU‑origin manufacturing ensures compliance with stringent quality standards, making it comparable to other high‑grade amino acid solutions used in clinical nutrition.

The product must be stored refrigerated at 2‑8 °C. Keep it in the original container, protect from light, and avoid freezing or shaking. If the solution reaches room temperature, it should be used promptly and not re‑refrigerated.

Kidiamix G Start is administered intravenously, typically via a central or peripheral venous catheter. The infusion rate is set by the prescribing clinician based on the patient’s metabolic needs and is monitored continuously for tolerance and safety.

Serious risks include anaphylactic reactions, metabolic acidosis, and renal dysfunction, especially in patients with pre‑existing kidney disease. Immediate discontinuation and appropriate medical intervention are required if any of these events occur.

Kidiamix G Start should be avoided in patients with known hypersensitivity to any of its amino acid components, in those with uncontrolled hyperkalemia, or in individuals where compatible IV solutions cannot be ensured due to incompatibility risks.